Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Possibilities of the individualized approach to normothymic therapy in bipolar affective disorder

Kostyukova E.G.
Federal Medical Research Centre of Psychiatry and Narcology of Ministry of health of the Russian Federation

SUMMARY: The article is devoted to the analysis of the literature data concerning the features of clinical action of traditionally used normothymics for the purpose of creation of the individualized approach to maintenance therapy of bipolar affective disorder. The results of studies of lithium and normothymics antikonvulsants showing the comparable efficiency of preventive action, but various spectrums of normothymic activity which can be used as a reference point for primary choice depending on a clinical picture and a course of a patient’s disease. Also the results of own research showing that the type of bipolar disorderis the main prognostic factor of efficacy of preventive therapy with antikonvulsants.

References: 
  • 1. Keck P.E., McElroy S.L., Strakowski SM et al. Outcome and comorbidity in first-episode compared with multiple-episode mania // J Nerv Ment Dis. – 1995. – No 183. – P. 320–324.
  • 2. Post R.M., Rubinow D.R., Ballenger J.C. Conditioning and sensitization in the longitudinal course of affective illness // Br J Psychiatry. – 1986. – No 149. – P. 191–201.
  • 3. Kraepelin E. Manisch-depressives Irresein und Paranoia. – 1921.
  • 4. Zis A.P., Grof P., Webster M., Goodwin F.K. Prediction of relapse in recurrent affective disorder // Psychopharmacol Bul. – 1980. – Vol. 16. – P. 47–49.
  • 5. Angst J. Course of affective disorders. In: van Praag H.M., Lader H.M., Rafaelson O.J., Sachar E.J. (eds.) Handbook of Biological Psychiatry. – New York: Marcel Dekker, 1981. – P. 225–242.
  • 6. Roy-Byrne P.P., Post R.M., Uhde T.W., Porcu T., Davis D. The longitudinal course of recur- rent affective illness: life chart data from research patients at the NIMH // Acta Psychiatr Scand. – 1985. – Suppl. 317. – P. 1–34.
  • 7. Kessing L.V. Recurrence in affective disorders // British J Psychiatry. – 1998. – Vol. 172. – P. 23–28.
  • 8. Kessing L.V. Cognitive impairment in the euthymic phase of affective disorder // Psychol Med. – 1998. – Vol. 28. – P. 1027–1038.
  • 9. Lopez-Jaramillo C., Lopera-Vasquez J., Gallo A., Ospina-Duque J., Bell V., Torrent C., Mar- tinez-Aran A., Vieta E. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence // Bipolar Disord. – 2010. – Vol. 12. – P. 557–567.
  • 10. Goodwin G.M., Martinez-Aran A., Glahn D.C. et al. Cognitive Impairment in Bipolar Disorder: Neurodevelopment or Neurodegeneration? An ECNP expert meeting report // Eur Neuropsychopharmacol. – 2008. – Vol. 18. – P. 787–793.
  • 11. Martinez-Arán A., Vieta E., Colom F. et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome // Bipolar Disord. – 2004. – Vol. 6. – P. 224–232.
  • 12. Dickerson F.B., Boronow J.J., Stallings C.R., Origoni A.E., Cole S., Yolken R.H. Association between cognitive functioning and employment status of persons with bipolar disorder // Psychiatr Serv. – 2004. – Vol. 55. – P. 54–58.
  • 13. Wingo A.P., Harvey P.D., Baldessarini R.J. Neurocognitive impairment in bipolar disorder pa- tients: functional implications // Bipolar Disord. – 2009. – Vol. 11. – P. 113–125.
  • 14. Eduard Vieta (eds.) Managing Bipolar Disorder in Clinical Practice. Second ed.– 2009. – P. 127.
  • 15. Frye M.A., Ketter T.A., Kimbrell T.A., Dunn R.T., Speer A.M., Osuch E.A., Luckenbaugh D.A., Cora-Ocatelli G., Leverich G.S., Post R.M. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders // Journal of Clinical Psychopharmacology. – 2000, Dec. – Vol. 20 (6). P. 607–614.
  • 16. McElroy S.L., Suppes T., Keck P.E., Frye M.A., Denicoff K.D., Altshuler L.L., Brown E.S., Nolen W.A., Kupka R.W., Rochussen J., Leverich G.S., Post RMOpen-label adjunctive topiramate in the treatment of bipolar disorders // Biol Psychiatry. – 2000, Jun 15. – Vol. 47 (12). – P.1025–1033.
  • 17. Eads L.A., Kramer T. Effects of topiramate on global functioning in treatment-refractory mood disorders // Abstract submitted to the 22nd Congress of the Collegium Internationale Neuro-Psychopharmacolgicum. – Brussels, Belgium, 2000.
  • 18. Ghaemi S.N., Manwani S.G., Katzow J.J., Ko J.Y., Goodwin F.K. Topiramate treatment of bipolar spectrum disorders: a retrospective chart review // Ann Clin Psychiatry. – 2001. – Vol. 13. – P. 185–189. – doi: 10.1023/A:1014627001201/
  • 19. Vieta E., Torrent C., Garcia-Ribas G., Gilabert A., Garcia-Pares G., Rodriguez A., Cadevall J., Garcia-Castrillon J., Lusilla P., Arrufat F. Use of topiramate in treatment-resistant bipolar spectrum disorders // J Clin Psychopharmacol. – 2002. – Vol. 22. – P. 431–435. – doi: 10.1097/00004714-200208000-00017
  • 20. Vieta E., Ros S., Valle J., Crespo J.M., Valls J., Salgado P. A multicentre study of the efficacy and safety of topiramate in mania // 23rd Congress of the Collegium of Internationale Psychopharmacologieum. – Montreal, Canada, 2002;
  • 21. Maidment I.D. Gabapentin treatment for bipolar disorders // Ann Pharmacother. – 2001, Oct. – Vol. 35 (10). P. 1264–1269.
  • 22. Panteleeva G.P., Rayushkin V.A., Snedkova L.V. Nekotorye podhody k optimizacii profilakticheskoj terapii affektivnyh psihozov // Materialy XII s"ezda psihiatrov Rossii. – 1995. – S. 542–543.
  • 23. Baastrup P.C., Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis // Arch Gen Psychiatry. – 1967. – Vol. 16. – P. 162–172.
  • 24. Coppen A., Nogguern R., Bailey J. et al. Prophylactic lithium in affective disorders: Controlled trial // Lancet. – 1971. – Vol. 2. – P. 275–279.
  • 25. Cundall R.L., Brooks P.W. and Murray L.G. A controlled evaluation of lithium prophylaxis in affective disorders // Psychol Med. – 1972. – Vol. 2. – P. 308–311.
  • 26. Fieve R.R., Kumbaraci R. and Dunner D.L. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients // Am J Psychiatr. – 1976. – Vol. 133 (8). – P. 925–929.
  • 27. Dunner D.L., Fleiss J.L. and Fieve R.R. Lithium carbonate prophylaxis failure // Br J Psychiatr. – 1976. – Vol. 129. – P. 40–44.
  • 28. Prien R.F., Klett C.J., Caffey E.M. Lithium carbonate and imipramine in the prevention of affective episodes // Arch Gen Psychiatry. – 1973. – Vol. 29. – P. 420–424.
  • 29. Maj M., Pirozzi R., Magliano L., Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic // Am J Psychiatry. – 1998. – Vol. 155. – P. 30–35.
  • 30. Gitlin M. Lithium and the kidney: an updated review // Drug Saf. – 1999. – Vol. 20. – P. 231–243.
  • 31. Calabrese J., Bowden C.L., Sachs G., Yatham L.N., Behnke K., Mehtonen O.-P., Montgomery P., Ascher J., Paska W., Earl N.L., DeVeaugh-Geiss J., for the Lamictal 605 Study group. A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients with Bipolar I Disorder // J Clin Psychiatry. – 2003. – Vol. 64. – P. 1024.
  • 32. Bowden C.L., Calabrese J.R., Sachs G., Yatham L.N., Asghar S.A., Hompland M., Montgomery P., Earl N., Smoot T.M., De Veaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder // Arch Gen Psychiatry. – 2003. – Vol. 60. – P. 392–400.
  • 33. Weisler R.H., Nolen W.A., Neijber A., Hellqvist A., Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study) // J Clin Psychiatry. – 2011.
  • 34. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G., Chou J.C., Keck P.E., Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group // Arch Gen Psychiatry. – 2000. – Vol. 57. – P. 481–489.
  • 35. Gelenberg A.J., Kane J.M., Keller M.B. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders // N Engl J Med. – 1989. – Vol. 321. – P. 1489–1493.
  • 36. Arnold O.H. Beobachtungen zum “automatenhaften Dasein” unter Lithium-langzeit-Therapie-Arzneimittel Forsh. – 1974. – Bd. 34. – S. 1125–1127.
  • 37. Gyulai L., Bowden C.L., McElroy S.L., Calabrese J.R., Petty F., Swann A.C., Chou J.C., Wassef A., Risch C.S., Hirschfeld R.M., Nemeroff C.B., Keck P.E., Jr., Evans D.L., Wozniak P.J. Main- tenance efficacy of divalproex in the prevention of bipolar depression // Neuropsychopharmacology. – 2003. – Vol. 28. – P. 1374–1382.
  • 38. McElroy S.L., Bowden C.L., Collins M.A., Wozniak P.J., Keck P.E., Jr., Calabrese J.R. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder // J Affect Disord. – 2008. – Vol. 107. – P. 127–133.
  • 39. Tohen M., Ketter T.A., Zarate C.A. et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study // Am J Psychiatry. – 2003. – Vol. 160. – P. 1263–1271.
  • 40. Bowden C.L., Singh V., Weisler R., Thompson P., Chang X., Quinones M., Mintz J. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression // Acta Psychiatr Scand. – 2012, Nov. – No 126 (5). – P. 342–350.
  • 41. Marcus R., Khan A., Rollin L., Morris B., Timko K., Carson W., Sanchez R. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study // Bipolar Disord. – 2011. – Vol. 13. – P. 133–144.
  • 42. Bowden C.L., Vieta E., Ice K.S., Schwartz J.H., Wang P.P., Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial // J Clin Psychiatry. – 2010. – Vol. 71. – P. 130–137.
  • 43. Lambert P.A. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide) // Emrich H.M., Okuma T., Muller A.A. (eds.) Anticonvulsants and Affective Disorders Amsterdam: Elsevier Science Puplishers. – 1984. – P. 33–44.
  • 44. Mosolov S.N. Obryv kontinual'nogo techeniya affektivnyh kolebanij s pomoshch'yu karbamazepina i val'proata natriya u rezistentnyh k lecheniyu solyami litiya bol'nyh endogennymi psihozami // Psihopatologicheskie i patogeneticheskie aspekty prognoza i terapii depressij. – M., 1986. – S. 75–80.
  • 45. Calabrese J.R., Deluccni G.A. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder // Am J Psychiat. – 1990. – Vol. 147. – P. 431–434.
  • 46. Mosolov S.N. Sravnitel'naya effektivnost' profilakticheskogo primeneniya karbonata litiya, karbamazepina i val'proata natriya pri affektivnyh i shizoaffektivnyh psihozah // Zhurn. nevropatol. i psihiatr. im. S.S. Korsakova. – 1991. – No 4. – S. 78–83.
  • 47. Guscott R. Clinical experience with valproic acid in 22 patients with refractory bipolar mood disorder // Can J Psychiatry. – 1992. – Vol. 37 (8). – P. 590.
  • 48. Sharma V. Persad E., Mazmanian D. et al. Treatment of cycling bipolar disorder with com- bination therapy of valproate and lithium // Can J Psychiatry. – 1993. – Vol. 38, No 2. – P. 137–139.
  • 49. Mosolov S.N. Hronobiologicheskie aspekty normotimicheskogo dejstviya antikonvul'santov i solej litiya (eksperimental'noe i klinicheskoe polisomnograficheskie issledovaniya) // Antikonvul'sany v psihiatricheskoj i nevrologicheskoj praktike / Vejn A.M., Mosolov S.N., red. Medicinskoe informacionnoe agentstvo. – M., 1994. – S. 129–252.
  • 50. Revicki D.A., Hirschfeld R.M.A., Ahearn E.P. et al. Effectiveness and medical costs of dival- proex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial // J Affect Disord. – 2005. – Vol. 86. – P. 183–193.
  • 51. Kuzavkova M.V., Kostyukova E.G., Mosolov S.N. Kliniko-farmakokineticheskij prognoz effektivnosti antikonvul'santov normotimikov i solej litiya pri vtorichnoj profilaktike shizoaffektivnogo i affektivnogo psihozov // Mosolov S.N., red. Novye dostizheniya v terapii psihicheskih zabolevanij. – M., 2002. – S. 356–372.
  • 52. Mosolov S.N., Kostyukova E.G., Fedotov D.D. Sravnitel'naya effektivnost' i perenosimost' profilakticheskoj terapii i karbonatom litiya i val'proatom natriya u bol'nyh bipolyarnym affektivnym rasstrojstvom posle kupirovaniya maniakal'nogo epizoda // Psihicheskoe zdorov'e. – 2009. – No 11. – S. 32–39.
  • 53. Fedotov D.D., Kostyukova E.G., Ladyzhenskij M.Ya., Mosolov S.N. (red.) Profilakticheskoe primenenie val'proata natriya, lamotridzhina i topiramata u bol'nyh s bipolyarnym affektivnym rasstrojstvom s chastymi recidivami // Biologicheskie metody terapii psihicheskih rasstrojstv. Dokazatel'naya medicina – klinicheskoj praktike. M., 2012. – S. 586–623.
  • 54. Greil W., Ludwig-Mayerhofer W., Erazo N., Scho ̈ midt C., Schmidt S., Engel R.R., Czernik A., Giedke H., Mu ̈ller-Oerlinghausen B., Osterheider M., Rudolf G.A., Sauer H., Tegeler J., Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders – a randomised study // J Affect Disord. – 1997. – Vol. 43. – P. 151–161.
  • 55. Greil W., Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified // Int Clin Psychopharmacol. – 1999. – Vol. 14. – P. 283–285.
  • 56. Greil W., Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder // Int Clin Psychopharmacol. – 1999. – Vol. 14. – P. 277–281.
  • 57. Greil W., Ludwig-Mayerhofer W., Erazo N., Engel R.R., Czernik A., Giedke H., Muller-Oerlinghausen B., Osterheider M., Rudolf G.A., Sauer H., Tegeler J., Wetterling T. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study // Eur Arch Psychiatry. Clin Neurosci. – 1997. – Vol. 247. – P. 42–50.
  • 58. Coxhead N., Silverstone T., Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder // Acta Psychiatr Scand. – 1992. – Vol. 85. – P. 114–118.
  • 59. Hartong E.G., Moleman P., Hoogduin C.A., Broekman T.G., Nolen W.A. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients // J Clin Psychiatry. – 2003. – Vol. 64. – P. 144–151.
  • 60. Lusznat R.M., Murphy D.P., Nunn C.M. Carbamazepine vs lithium in the treatment and prophylaxis of mania // Br J Psychiatry. – 1988. – Vol. 153. – P. 198–204.
  • 61. Placidi G.F., Lenzi A., Lazzerini F., Cassano G.B., Akiskal H.S. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients // J Clin Psychiatry. – 1986. – Vol. 47. – P. 490–494.
  • 62. Watkins S.E., Callender K., Thomas D.R., Tidmarsh S.F., Shaw D.M. The effect of carbamazepine and lithium on remission from affective illness // Br J Psychiatry. – 1987. – Vol. 150. – P. 180–182.
  • 63. Denicoff K.D., Smith-Jackson E.E., Disney E.R., Ali S.O., Leverich G.S., Post R.M. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder // J Clin Psychiatry. – 1997. – Vol. 58. – P. 470–478.
  • 64. Takezaki H., Hanaoka H. The use of carbamazepine (Tegretol) in the control of manic-depressive states // Clin Psyhiat. – 1971. – Vol. 13, No 2. – P. 173–183.
  • 65. Ballenger J.C., Post R.M. Carbamazepine in manic-depressive illness: A new treatment // Am. J. Psychiatry. – 1980. – Vol. 137. – P. 782–790.
  • 66. Okuma T. Therapeutic and prophylactic efficasy of carbamazepine in manic depressive psy- chisis. In: Anticonvulsants in Affective Disorders, Emrich H.M., Okuma T., Muller A.A. (eds.) // Elsevier Science Publishers, Amsterdam, 1984.
  • 67. Vovin R.Ya., Digilov A.G. Skorik A.i. Profilakticheskoe lechenie affektivnyh psihozov finlepsinom // Zhurn. nevropatol. i psihiatr. im. S.S. Korsakova. – 1984. – № 8. – S. 1226–1230.
  • 68. Kostyukova E.G. Sravnitel'nye osobennosti profilakticheskogo dejstviya karbamazepina i karbonata litiya pri affektivnyh i shizoaffektivnyh psihozah // Zh-l nevropatologii i psihiatrii im. S.S. Korsakova. – 1989. – T. 88, vyp. 12.
  • 69. Kostyukova E.G., Rayushkin V.A., Ushakov Yu.V. Profilaktika recidivov affektivnogo i shizoaffektivnogo psihoza s pomoshch'yu karbamazepina (met. rek. pod nauchn. ruk. G.P. Panteleevoj). – M., 1991.
  • 70. Kuzavkova M.V. Kliniko-farmakokineticheskij prognoz effektivnosti normotimikov pri vtorichnoj profilaktike faznoprotekayushchih endogennyh psihozov: diss. … kand. med. nauk. – M., 2001.
  • 71. Bowden C.L., Calabrese J.R., Sachs G. et al. A randomized, placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder // Scientific Abstracts of the 40th Annual Meeting of the American College of Neuropsychopharmacology. – 2001, Dec 9–13. – Waikoloa, HI. – P. 238.
  • 72. Bowden C.L., Ghaemi N., Gyulai L. et al. Lamotrigine delays mood episodes in recently de- pressed bipolar I patients. /In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association. – 2002, May 18–23. – Philadelphia, PA. – P. 81.
  • 73. Goodwin G.M., Bowden C.L., Calabrese J.R., Grunze H., Kasper S., White R., Greene P., Lead- better R. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder // J Clin Psychiatry. – 2004. – Vol. 65. – P. 432–441.
  • 74. Calabrese J.R., Goldberg J.F., Ketter T.A., Suppes T., Frye M., White R., Veaugh-Geiss A., Thompson T.R. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies // Biol Psychiatry. – 2006. – Vol. 59. – P. 1061–1064.
  • 75. Singh V., Mintz J., Tohen M. Novel strategies to improve generalizability of maintenance trial results in Bipolar Disorder (BD) // Bipolar Disord. – 2012yu – Vol. 14 (Suppl. 1). – P. 13–14.
  • 76. Smith L.A., Cornelius V., Warnock A., Bell A., Young A.H. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials // Bipolar Disord. – 2007. – Vol. 9. – P. 394–412.
  • 77. Beynon S., Soares-Weiser K., Woolacott N., Duffy S., Geddes J.R. Pharmacological interven- tions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials // J Psychopharmacol, 2009. – Vol. 23. – P. 574–591.
  • 78. Vieta E., Grunze H. Bipolar disorder – a focus on depression // N Engl J Med. – 2011. – Vol. 364. – P. 1581.
  • 79. Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence // Bipolar Disord. – 2000. – Vol. 2. – P. 93–101.
  • 80. Solomon D.A. Keitner G.I., Miller I.W. et al. Course of illness and maintenance treatments for patients with bipolar disorder // J Clin Psychiatry. – 1995. –Vol. 6. – P. 5–13.
  • 81. Mosolov S.N., Kostyukova E.G., Kuzavkova M.V. Bipolyarnoe affektivnoe rasstrojstvo. Diagnostika i terapiya. – M.: Medpress-inform, 2008.
  • 82. Grof P. Some practical aspects of lithium treatment: blood levels, dosage prediction, and slow- release preparations // Arch Gen Psychiatry. – 1979. – Vol. 36. – P. 891–893.
  • 83. Prien R.F., Kupfer D.J., Manskey P.A. et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine and lithium carbonate – imipramine carbonate combination // Arch Gen Psychiatry. – 1984. – Vol. 41. – P. 1096–1104.
  • 84. Mosolov S.N. Primenenie solej litiya v psihiatricheskoj praktike. – M., 1983. – 38 s.
  • 85. Secunda S.K., Katz M.M., Swann A. et al. Mania: diagnosis, state measurement and prediction of treatment response // J Affect Disord. – 1985. – Vol. 8. – P. 113–121.
  • 86. Mosolov S.N. Sravnitel'naya effektivnost' profilakticheskogo primeneniya karbonata litiya, karbamazepina i val'proata natriya pri affektivnyh i shizoaffektivnyh psihozah // Zhurn. nevropatol. i psihiatr. im S.S. Korsakova. – 1991. – No 4. – S. 78–83.
  • 87. Mosolov S.N. hronobiologicheskie aspekty normotimicheskogo dejstviya antikonvul'santov i solej litiya (eksperimental'noe i klinicheskoe polisomnograficheskie issledovaniya) // Vejn A.M., Mosolov S.N., red. Antikonvul'sany v psihiatricheskoj i nevrologicheskoj praktike pod red. Medicinskoe informacionnoe agentstvo. – M., 1994. – S. 129–252.
  • 88. Mosolov S.N. Osnovy psihofarmakoterapii // Vostok. – 1996. – 374 s.
  • 89. Mosolov S.N. Primenenie karbamazepina i val'proata natriya u bol'nyh endogennymi psihozami, oslozhnennyh nepreryvnym techeniem kolebanij i rezistentnyh k terapii solyami litiya // V Vserossijskij s"ezd nevropatologov i psihiatrov: tez. dokl. – M., 1985. – № 3. – S. 297–299.
  • 90. Mosolov S.N. Klinika i terapiya zatyazhnyh (stacionarnyh i labil'no-kontinual'nyh) form faznoprotekayushchih psihozov (kliniko-eksperimental'noe issledovanie): dis. … d-ra med. nauk. – M.,1992. – T. 2. – S. 307–322.
  • 91. Emrich H.M., Dose M., Von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders // J Affect Disord. – 1985. – No 8. – P. 243–250.
  • 92. McElroy S.L., Dessain E.C., Pope H.G. Jr. Mixed states and bipolar rapid cycling and their treatment with valproate // Am J Psychiatry. – 1994. – No 151. – P. 825–835;
  • 93. Calabrese J.R., Shelton M.D., Bowden C.L. et al. Bipolar rapid cycling: Focus on depression as its hallmark // J Clin Psychiatry 2001. – Vol. 62 (Suppl. 14). – P. 34–41.
  • 94. Schneck C.D. Bipolar Disorder in Neurologic Illness // Curr Treat Options Neurol. – 2002. – Vol. 4. – P. 477–486.
  • 95. Goncalves N., Stoll K.-D. Carbamazepin bei manischen Syndromen. Eine kontrollierte Doppel-blind-Studie // Nervenarzt. – 1985. – Vol. 56. – P. 43–47.
  • 96. Elphick M. An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo- affective psychotics // Br J Psychiatry, 1985. – Vol. 147. – P. 198–200.
  • 97. Fedotov D.D., Kostyukova E.G., Mosolov S.N. Sravnitel'naya effektivnost' i perenosimost' val'proata natriya, lamotridzhina i topiramata pri profilakticheskoj terapii bipolyarnogo i shizoaffektivnogo rasstrojstv // Social'naya i klinicheskaya psihiatriya – 2010. – № 2. – C. 72–79.
  • 98. Fedotov D.D., Kostyukova E.G., Mosolov S.N. Differencirovannyj prognoz effektivnosti profilakticheskoj terapii lamotridzhinom, val'proatom i topiramatom u bol'nyh s chastymi recidivami BAR pervogo i vtorogo tipov // Social'naya i klinicheskaya psihiatriya. – 2014. – T. 24, № 3. – S. 77–83.